Literature DB >> 12528323

[The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna].

Stefan Oberndorfer1, Thomas Schmal, Heinz Lahrmann, Sabine Urbanits, Klaus Lindner, Wolfgang Grisold.   

Abstract

Epileptic seizures are common in patients with cerebral metastases as well as in patients with primary brain tumors. In cancer patients without primary brain tumors or brain metastasis, epileptic seizures may occur due to metabolic or toxic causes, or due to infections. We performed a retrospective analysis from our neurooncological database concerning the occurrence of seizures in patients with primary brain tumors, patients with cerebral metastases and in cancer patients without brain tumors. Patients with low grade gliomas, such as astrocytoma WHO I + II (69%), oligodendroglioma WHO II (50%), and mixed glioma WHO II-III (56%) were more likely to have seizures than patients with anaplastic glioma WHO III (44%), glioblastoma WHO IV (48%) or meningeoma (45%). In patients with brain metastasis, melanoma (67%), cancer of the lung (29%), and gastrointestinal tumors (21%) were the primaries with the highest frequency of seizures. In cancer patients without brain metastases or primary brain tumors, seizures occurred in 4%. In conclusion, the occurrence of epileptic seizures in patients suffering from primary brain tumors, as well as in patients with cerebral metastases, varied within the tumor entity. Therefore, especially in brain tumors where a higher probability of epileptic seizures is expected, they should be taken into account in the care of cancer patients.

Entities:  

Mesh:

Year:  2002        PMID: 12528323

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  25 in total

Review 1.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

2.  [Supportive care and palliation in patients with malignant gliomas].

Authors:  Stefan Oberndorfer; Heinz Lahrmann
Journal:  Wien Med Wochenschr       Date:  2006-06

3.  Seizure prophylaxis and melanoma brain metastases.

Authors:  S A Goldlust; M Hsu; A B Lassman; K S Panageas; E K Avila
Journal:  J Neurooncol       Date:  2012-02-05       Impact factor: 4.130

Review 4.  Epilepsy in brain metastasis: an emerging entity.

Authors:  Roberta Rudà; Francesca Mo; Alessia Pellerino
Journal:  Curr Treat Options Neurol       Date:  2020-02-08       Impact factor: 3.598

Review 5.  Glutamate and tumor-associated epilepsy: glial cell dysfunction in the peritumoral environment.

Authors:  Susan C Buckingham; Stefanie Robel
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

6.  Inhibition of cystine uptake disrupts the growth of primary brain tumors.

Authors:  Wook Joon Chung; Susan A Lyons; Gina M Nelson; Hashir Hamza; Candece L Gladson; G Yancey Gillespie; Harald Sontheimer
Journal:  J Neurosci       Date:  2005-08-03       Impact factor: 6.167

Review 7.  Treatment of Brain Metastases.

Authors:  Xuling Lin; Lisa M DeAngelis
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

Review 8.  A role for glutamate in growth and invasion of primary brain tumors.

Authors:  Harald Sontheimer
Journal:  J Neurochem       Date:  2008-02-14       Impact factor: 5.372

9.  Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB.

Authors:  W Joon Chung; Harald Sontheimer
Journal:  J Neurochem       Date:  2009-04-29       Impact factor: 5.372

Review 10.  Seizures and epilepsy in cancer: etiologies, evaluation, and management.

Authors:  Jai Grewal; Harpreet K Grewal; Arthur D Forman
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.